248 related articles for article (PubMed ID: 28088309)
21. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?
Hutchings M
Hematology Am Soc Hematol Educ Program; 2012; 2012():322-7. PubMed ID: 23233599
[TBL] [Abstract][Full Text] [Related]
22. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
24. The treatment of older Hodgkin lymphoma patients.
Böll B; Görgen H
Br J Haematol; 2019 Jan; 184(1):82-92. PubMed ID: 30407626
[TBL] [Abstract][Full Text] [Related]
25. Recent treatment advances in Hodgkin lymphoma: a concise review.
Arulogun S; Hertzberg M; Gandhi MK
Intern Med J; 2016 Dec; 46(12):1364-1369. PubMed ID: 26929077
[TBL] [Abstract][Full Text] [Related]
26. Novel treatment concepts in Hodgkin lymphoma.
Glimelius I; Diepstra A
J Intern Med; 2017 Mar; 281(3):247-260. PubMed ID: 27991731
[TBL] [Abstract][Full Text] [Related]
27. Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma.
Gordon LI
J Natl Compr Canc Netw; 2017 May; 15(5S):716-718. PubMed ID: 28515253
[TBL] [Abstract][Full Text] [Related]
28. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.
Dozzo M; Zaja F; Volpetti S; Sperotto A; Magli A; Fanin R
Am J Hematol; 2015 Apr; 90(4):E73. PubMed ID: 25546725
[No Abstract] [Full Text] [Related]
30. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
31. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
32. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
33. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
34. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
35. [Classic Hodgkin lymphoma].
Makita S
Rinsho Ketsueki; 2023; 64(6):504-513. PubMed ID: 37407475
[TBL] [Abstract][Full Text] [Related]
36. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma.
Crocchiolo R; Fallanca F; Giovacchini G; Ferreri AJ; Assanelli A; Verona C; Pescarollo A; Bregni M; Ponzoni M; Gianolli L; Fazio F; Ciceri F
Ann Hematol; 2009 Dec; 88(12):1229-36. PubMed ID: 19468730
[TBL] [Abstract][Full Text] [Related]
37. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.
Nagai H
Jpn J Clin Oncol; 2015 Feb; 45(2):137-45. PubMed ID: 25489004
[TBL] [Abstract][Full Text] [Related]
39. Multimodality imaging using PET/CT (
Édeline V; Remouchamps V; Isnardi V; Vander Borght T
Cancer Radiother; 2018 Sep; 22(5):384-392. PubMed ID: 30055933
[TBL] [Abstract][Full Text] [Related]
40. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.
Michot JM; Lazarovici J; Ghez D; Danu A; Fermé C; Bigorgne A; Ribrag V; Marabelle A; Aspeslagh S
Eur J Cancer; 2017 Nov; 85():67-77. PubMed ID: 28892775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]